Why the study?
Does acarbose reduce the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance?
Does acarbose reduce the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance?
Acarbose treatment may be associated with a reduced risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance.
Answers are grounded in this paper and cite their sources.
Supports acarbose in IGT to lower CVD and hypertension risk; extends glycemic data to cardiovascular outcomes.
This study suggests that treating IGT patients with acarbose is associated with a significant reduction in the risk of cardiovascular disease and hypertension.
No takes yet. Share an insight, caveat, or question.
Chiasson et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: